AR002002A1 - USE OF THE EPIDERMIC GROWTH FACTOR IN THE MANUFACTURE OF A MEDICINE IN THE FORM OF HYDROPHILIC CREAM FOR THE TREATMENT OF ACNE. - Google Patents
USE OF THE EPIDERMIC GROWTH FACTOR IN THE MANUFACTURE OF A MEDICINE IN THE FORM OF HYDROPHILIC CREAM FOR THE TREATMENT OF ACNE.Info
- Publication number
- AR002002A1 AR002002A1 ARP950100314A AR10031495A AR002002A1 AR 002002 A1 AR002002 A1 AR 002002A1 AR P950100314 A ARP950100314 A AR P950100314A AR 10031495 A AR10031495 A AR 10031495A AR 002002 A1 AR002002 A1 AR 002002A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- acne
- egf
- medicine
- manufacture
- Prior art date
Links
- 208000002874 Acne Vulgaris Diseases 0.000 title abstract 4
- 206010000496 acne Diseases 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 239000008309 hydrophilic cream Substances 0.000 title abstract 2
- 239000003102 growth factor Substances 0.000 title 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 3
- 101800003838 Epidermal growth factor Proteins 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 229940116977 epidermal growth factor Drugs 0.000 abstract 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 abstract 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 abstract 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 abstract 2
- 239000002562 thickening agent Substances 0.000 abstract 2
- 235000021355 Stearic acid Nutrition 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 239000003995 emulsifying agent Substances 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 239000003906 humectant Substances 0.000 abstract 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 abstract 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 abstract 1
- 229960002216 methylparaben Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000000902 placebo Substances 0.000 abstract 1
- 229940068196 placebo Drugs 0.000 abstract 1
- 229910000027 potassium carbonate Inorganic materials 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 abstract 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 abstract 1
- 229960003415 propylparaben Drugs 0.000 abstract 1
- 239000008213 purified water Substances 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000008117 stearic acid Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/86—Products or compounds obtained by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención está relacionada con la rama de la Medicina y en particular con el empleo del Factor de Crecimiento Epidérmico (EGF) humano yrecombinante en la fabricación de un medicamento para el tratamiento del acné. La composición consiste en una crema hidrófila a base de ácido esteárico comoespesante, carbonato de potasio anhidro como emulsionante y espesante, metilparabeno y propilparabeno como preservativo antimicrobiano, glicerina comohumectante y agua purificada como disolvente y una cantidad de EGF que oscila entre 2 y 50 µg/g, preferiblemente 10 µg/g. Su objetivo técnico es lograr unproducto eficaz para el tratamiento de esta enfermedad crónica de la piel con implicaciones estéticas y psicológicas, demostrándose la utilidad de esteprincipio activo para la fabricación de un medicamento para el tratamiento de dicha patología en un ensayo clínico realizado a doble ciego. De un total de 30pacientes con acné activo tratados diariamente durane 90 días, se determinó el grado de afección según la escala de 8 grados del Colegio Médico UniversitarioInglés, al inicio, a los 45 días y al finalizar el tratamiento. El grupo tratado con EGF presentó mejoría sgnificativa (p<0,01) con respecto al querecibió placebo, encontrándose en el grupo que se utilizó EGF una mejoría general en 23 pacientes (79,3%), destacándose de ellos 15 (51,7%) mucho mejor y8(27,5%) mejor. Ningún paciente empeoró. Esta invención puede emplearse como alternativa terapéutica para el tratamiento del acné crónico.The present invention is related to the branch of Medicine and in particular to the use of the human and recombinant Epidermal Growth Factor (EGF) in the manufacture of a medicine for the treatment of acne. The composition consists of a hydrophilic cream based on stearic acid as a thickener, anhydrous potassium carbonate as an emulsifier and thickener, methylparaben and propylparaben as an antimicrobial preservative, glycerin as a humectant and purified water as a solvent and an amount of EGF ranging from 2 to 50 µg / g, preferably 10 µg / g. Its technical objective is to achieve an effective product for the treatment of this chronic skin disease with aesthetic and psychological implications, demonstrating the usefulness of this active principle for the manufacture of a drug for the treatment of said pathology in a double-blind clinical trial. Out of a total of 30 patients with active acne treated daily for 90 days, the degree of affection was determined according to the 8-degree scale of the English University Medical College, at the beginning, at 45 days and at the end of treatment. The group treated with EGF showed significant improvement (p <0.01) with respect to that received placebo, finding in the group that used EGF a general improvement in 23 patients (79.3%), 15 of them standing out (51.7 %) much better and 8 (27.5%) better. No patient worsened. This invention can be used as a therapeutic alternative for the treatment of chronic acne.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU1994136A CU22613A1 (en) | 1994-11-25 | 1994-11-25 | USE OF EPIDERMIC GROWTH FACTOR FOR THE TREATMENT OF ACNE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR002002A1 true AR002002A1 (en) | 1998-01-07 |
Family
ID=46093359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP950100314A AR002002A1 (en) | 1994-11-25 | 1995-11-24 | USE OF THE EPIDERMIC GROWTH FACTOR IN THE MANUFACTURE OF A MEDICINE IN THE FORM OF HYDROPHILIC CREAM FOR THE TREATMENT OF ACNE. |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR002002A1 (en) |
| CU (1) | CU22613A1 (en) |
| WO (1) | WO1996016669A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170202917A1 (en) * | 2014-05-29 | 2017-07-20 | Daewoong Pharmaceutical Co., Ltd. | Pharmaceutical composition for preventing or treating skin rash |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3380839D1 (en) * | 1983-11-02 | 1989-12-21 | J C R Kabushiki Kaisha Also Kn | Ophthalmic preparations |
| US5023090A (en) * | 1989-08-16 | 1991-06-11 | Levin Robert H | Topical compositions containing LYCD and other topically active medicinal ingredients for the treatment of ACNE |
| CN1083371A (en) * | 1993-01-03 | 1994-03-09 | 周至惠 | Acne, folliculitis, erythra special nursing agent |
-
1994
- 1994-11-25 CU CU1994136A patent/CU22613A1/en unknown
-
1995
- 1995-11-17 WO PCT/NL1995/000392 patent/WO1996016669A1/en not_active Ceased
- 1995-11-24 AR ARP950100314A patent/AR002002A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996016669A1 (en) | 1996-06-06 |
| CU22613A1 (en) | 2000-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4826830A (en) | Topical application of glyciphosphoramide | |
| CA1338779C (en) | Method for treating pain associated with herpes-zoster and post-herpetic neuralgia by topical application of local anesthetics | |
| US7300666B2 (en) | Mixture for transdermal delivery of low and high molecular weight compounds | |
| ES2655876T3 (en) | Trigonella foenum-graecum extract | |
| US20110189307A1 (en) | Methods and compositions for oxygenation of skin to treat skin disorders | |
| EP1684681B1 (en) | A mixture for transdermal delivery of low and high molecular weight compounds | |
| JP7515277B2 (en) | Skin care product containing loxoprofen | |
| AR002002A1 (en) | USE OF THE EPIDERMIC GROWTH FACTOR IN THE MANUFACTURE OF A MEDICINE IN THE FORM OF HYDROPHILIC CREAM FOR THE TREATMENT OF ACNE. | |
| EP2810641B1 (en) | Topical pharmaceutical and medical device preparations containing combinations of sucralfate, hyaluronic acid, arginine and a natural moisturizing agent | |
| JP6656890B2 (en) | Filaggrin production promoter | |
| US9585962B1 (en) | Treatment for actinic keratoses | |
| PT1351694E (en) | Promoting cell regeneration and/or cell differentiation with non-metabolizable sugar and a polymeric absorbent | |
| Hay et al. | A single application of bifonazole 1% lotion in pityriasis versicolor | |
| US12090133B2 (en) | Topical composition | |
| ES2782826T3 (en) | Topical pharmaceutical or medical device preparations containing combinations of sucralfate, hyaluronic acid, arginine, and a natural wetting agent | |
| MX2025009125A (en) | "phyto-compositions" | |
| ES2433249T3 (en) | Extraction of skin changes | |
| ATE91079T1 (en) | SALICYLIC ACID AGENT AGAINST SCALPING SKIN DISEASES. | |
| HU207446B (en) | Method for producing medicinal preparation of local use | |
| ES2363539T3 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF XEROSTOMY. | |
| KR20250083499A (en) | Storage-stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions | |
| ITRM20130686A1 (en) | NEW COMPOSITION FOR TOPICAL USE | |
| TW202302628A (en) | Derived peptides of lactoferrin and a use thereof for promoting and/or increasing lipid synthesis | |
| Impey | X rays and high-tension electricity | |
| Swain | Topical 5‐fluorouracil for corns—an effective new treatment |